Delivery Order SPE2DX22D0099-SPE2D826FAG4F

AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $6,018.18 on February 2, 2026, by the Defense Logistics Agency's Medical Supply Chain. The contract carries a firm fixed-price structure with an ultimate completion date of February 3, 2026, and represents a non-set-aside competitive award. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent company, Cencora, Inc. (doing business as AmerisourceBergen), holds the primary IDC relationship with DLA and serves as a critical pharmaceutical vendor for military healthcare systems.

The delivery order falls within AmerisourceBergen's established role as a comprehensive pharmaceutical supply provider to federal medical procurement needs, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Through its DLA contract vehicle, the company supports military treatment facilities and veteran healthcare programs globally. The Defense Logistics Agency is actively planning to transition to the Pharmaceutical Prime Vendor Global Program Generation V structure, which will involve multiple awards to separate regional contractors, positioning vendors like AmerisourceBergen to continue supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract mechanisms.